Stay updated on IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.

Latest updates to the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThis updates the page’s displayed platform/interface revision from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check20 days agoChange DetectedThe history now includes Revision: v3.5.2 and removes Revision: v3.5.0.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedSystem revision history updated to add v3.5.0 and remove v3.4.3.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed from the history.SummaryDifference0.1%

- Check84 days agoChange DetectedThe page history shows a new revision (v3.4.2) replacing the previous revision (v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check91 days agoChange DetectedThe history now shows a new revision entry (v3.4.1) added to the record, and the previous revision (v3.4.0) has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.